Erik Deichmann Heegaard
Net worth: - $ as of 2024-05-30
Profile
Erik Deichmann Heegaard worked as a Medical Director in Novartis Corp.
He then worked as the Chief Medical Officer-GLP 1 Project in Novo Nordisk A from 2011 to 2014.
Currently, he is working as the Chief Medical Officer in Evaxion Biotech A from 2021 to 2023.
Dr. Deichmann Heegaard completed his undergraduate and doctorate degrees from the University of Copenhagen.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
EVAXION BIOTECH A/S
-.--% | 2023-03-30 | 0 ( -.--% ) | - $ | 2024-05-30 |
Former positions of Erik Deichmann Heegaard
Companies | Position | End |
---|---|---|
EVAXION BIOTECH A/S | Chief Tech/Sci/R&D Officer | 2023-02-28 |
NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 2013-12-31 |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Erik Deichmann Heegaard
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
EVAXION BIOTECH A/S | Health Technology |
NOVO NORDISK A/S | Health Technology |
Private companies | 1 |
---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Erik Deichmann Heegaard